Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 468537, 8 pages
http://dx.doi.org/10.1155/2013/468537
Research Article

Ocotillol Enhanced the Antitumor Activity of Doxorubicin via p53-Dependent Apoptosis

1Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education of China, School of Pharmacy, Yantai University, Yantai 264005, China
2State Key Laboratory of Long-Acting and Targeting Drug Delivery Technologies, Luye Pharma Group Ltd., Yantai 264003, China
3Center of Basic Medicine, Binzhou Medical College, Yantai 264005, China

Received 15 March 2013; Revised 23 May 2013; Accepted 28 May 2013

Academic Editor: Gautam Sethi

Copyright © 2013 Hongbo Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Lal, D. Enting, and H. Kristeleit, “Systemic treatment of non-small-cell lung cancer,” European Journal of Cancer, vol. 47, no. 3, supplement, pp. S375–S377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. R. Beil and L. M. Wein, “Sequencing surgery, radiotherapy and chemotherapy: insights from a mathematical analysis,” Breast Cancer Research and Treatment, vol. 74, no. 3, pp. 279–286, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Carvalho, R. X. Santos, S. Cardoso et al., “Doxorubicin: the good, the bad and the ugly effect,” Current Medicinal Chemistry, vol. 16, no. 25, pp. 3267–3285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos, “Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors,” Pharmacological Reviews, vol. 51, no. 4, pp. 691–743, 1999. View at Google Scholar · View at Scopus
  6. J. M. Scott, A. Khakoo, J. R. MacKey, M. J. Haykowsky, P. S. Douglas, and L. W. Jones, “Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms,” Circulation, vol. 124, no. 5, pp. 642–650, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-C. Marine, “Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX,” Cancer Cell, vol. 18, no. 5, pp. 399–400, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Harris and A. J. Levine, “The p53 pathway: positive and negative feedback loops,” Oncogene, vol. 24, no. 17, pp. 2899–2908, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Qian, Y. Yang, and X. Wang, “Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy,” European Journal of Pharmaceutical Sciences, vol. 43, no. 3, pp. 125–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Spina, L. Sorvillo, F. Di Maiolo et al., “Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway,” Journal of Cellular Physiology, vol. 228, no. 1, pp. 198–206, 2012. View at Google Scholar
  12. X.-W. Yuan, X.-F. Zhu, X.-F. Huang et al., “Interferon-α enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis,” Acta Pharmacologica Sinica, vol. 28, no. 11, pp. 1835–1841, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Schwartsmann, M. J. Ratain, G. M. Cragg et al., “Anticancer drug discovery and development throughout the world,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 47S–59S, 2002. View at Google Scholar · View at Scopus
  14. M. Karmazyn, M. Moey, and X. T. Gan, “Therapeutic potential of ginseng in the management of cardiovascular disorders,” Drugs, vol. 71, no. 15, pp. 1989–2008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L.-W. Qi, C.-Z. Wang, and C.-S. Yuan, “Ginsenosides from American ginseng: chemical and pharmacological diversity,” Phytochemistry, vol. 72, no. 8, pp. 689–699, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Wang, Q. Zheng, K. Liu, G. Li, and R. Zheng, “Ginsenoside Rh2 enhances antitumour activity and decreases genotoxic effect of cyclophosphamide,” Basic and Clinical Pharmacology and Toxicology, vol. 98, no. 4, pp. 411–415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Wang, P. Yu, and H. Gou, “Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 506214, 8 pages, 2012. View at Publisher · View at Google Scholar
  18. X. Xie, A. Eberding, C. Madera et al., “Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models,” Journal of Urology, vol. 175, no. 5, pp. 1926–1931, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. S.-W. Kim, H.-Y. Kwon, D.-W. Chi et al., “Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3,” Biochemical Pharmacology, vol. 65, no. 1, pp. 75–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Wang, H. Li, M. Zuo et al., “Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo,” Cancer Letters, vol. 268, no. 1, pp. 89–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Wang, X. Ma, S. Ren, J. K. Buolamwini, and C. Yan, “A small-molecule inhibitor of MDMX activates p53 and induces apoptosis,” Molecular Cancer Therapeutics, vol. 10, no. 1, pp. 69–79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Lizard, V. Deckert, L. Dubrez, M. Moisant, P. Gambert, and L. Lagrost, “Induction of apoptosis in endothelial cells treated with cholesterol oxides,” American Journal of Pathology, vol. 148, no. 5, pp. 1625–1638, 1996. View at Google Scholar · View at Scopus
  23. P. G. Komarov, E. A. Komarova, R. V. Kondratov et al., “A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy,” Science, vol. 285, no. 5434, pp. 1733–1737, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. T. J. Rutkoski and R. T. Raines, “Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity,” Current Pharmaceutical Biotechnology, vol. 9, no. 3, pp. 185–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Appel, D. Nielsen, B. Zerahn, B. V. Jensen, and K. Skagen, “Anthracycline-induced chronic cardiotoxicity and heart failure,” Acta Oncologica, vol. 46, no. 5, pp. 576–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Ahmad, W. A. Sakr, and K. M. W. Rahman, “Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy,” Current Drug Targets, vol. 11, no. 6, pp. 652–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Darzynkiewicz, S. Bruno, G. Del Bino et al., “Features of apoptotic cells measured by flow cytometry,” Cytometry, vol. 13, no. 8, pp. 795–808, 1992. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Levine and M. Oren, “The first 30 years of p53: growing ever more complex,” Nature Reviews Cancer, vol. 9, no. 10, pp. 749–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. J. Brown, S. Lain, C. S. Verma, A. R. Fersht, and D. P. Lane, “Awakening guardian angels: drugging the P53 pathway,” Nature Reviews Cancer, vol. 9, no. 12, pp. 862–873, 2009. View at Publisher · View at Google Scholar · View at Scopus